Biostax Corp (BTAX)

[locicat1]

Emphatic yes again regarding FDA approval. Just as a matter of very pertinent company history there was an FDA meeting to discuss the Phase 3 clinical development program for a proposed 505(b)(2) application for LDN in the treatment of adult and pediatric patients with Crohn's disease.The meeting was held on June 26, 2013 and the Company received the minutes from the meeting on July 17, 2013. That was over 4 1/2 years ago!!. Where does this historical info come from? Page 20 of the 3rd Quarter 2013 10 Q filing with the SEC.

What occurred to prevent development to proceed over this long period of time?? And since that time the patent that covers the use of LDN in Crohn's Disease was licensed to Cytocom, Inc., which IMUN now has only an approximately 10 % equity interest and maybe less at this time.